Estudio respirométrico de Lactobacillus casei ATCC 393 en presencia de iones Cu (II) y Zn (II)

Tesis (Maestría en Ciencias con Especialidad en Microbiología Industrial) UANL

Impacto de Lactobacillus casei Shirota en el desarrollo de Streptococcus mutans en pacientes con aparatología ortdóntica.

Tesis (Maestría en Ciencias Odontológicas en el área de Odontopediatría) UANL, 2014.

Selective effects of Lactobacillus casei Shirota on T cell activation, natural killer cell activity and cytokine production

Modulation of host immunity is an important potential mechanism by which probiotics confer health benefits. This study was designed to investigate the effects of a probiotic strain, Lactobacillus casei Shirota (LcS), on immune function, using human peripheral blood mononuclear cells (PBMC) in vitro. In addition, the role of monocytes in LcS-induced immunity was also explored. LcS promoted natural killer (NK) cell activity and preferentially induced expression of CD69 and CD25 on CD8+ and CD56+ subsets in the absence of any other stimulus. LcS also induced production of IL-1β, IL-6, TNF-α, IL-12 and IL-10 in the absence of lipopolysaccharide (LPS). In the presence of LPS, LcS enhanced IL-1β production, but inhibited LPS-induced IL-10 and IL-6 production, and had no further effect on TNF-α and IL-12 production. Monocyte-depletion significantly reduced the impact of LcS on lymphocyte activation, cytokine production and NK cell activity. In conclusion, LcS preferentially activated cytotoxic lymphocytes in both the innate and specific immune system, which suggests that LcS could potentiate the destruction of infected cells in the body. LcS also induced both pro-inflammatory and anti-inflammatory cytokine production in the absence of LPS, but inhibited LPS-induced cytokine production in some cases. Monocytes play an important role in LcS-induced immunological responses.

Survivability of a probiotic Lactobacillus casei in the gastrointestinal tract of healthy human volunteers and its impact on the faecal microflora

Aim: The aim of this study was to measure the gastrointestinal survival of Lactobacillus casei and its impact on the gut microflora in healthy human volunteers. Methods and Results: Twenty healthy volunteers took part in a double-blind placebo-controlled probiotic feeding study (10 fed probiotic, 10 fed placebo). The probiotic was delivered in two 65 ml aliquots of fermented milk drink (FMD) daily for 21 days at a dose of 8.6 +/- 0.1 Log(10)Lact. casei CFU ml(-1) FMD. Faecal samples were collected before, during and after FMD or placebo consumption, and important groups of faecal bacteria enumerated by fluorescent in situ hybridization (FISH) using oligonucleotide probes targeting the 16S rRNA. The fed Lact. casei was enumerated using selective nutrient agar and colony identity confirmed by pulsed field gel electrophoresis. Seven days after ingestion of FMD, the Lact. casei was recovered from faecal samples taken from the active treatment group at 7.1 +/- 0.4 Log(10) CFU g(-1) faeces (mean +/- SD, n = 9) and numbers were maintained at this level until day 21. Lact. casei persisted in six volunteers until day 28 at 5.0 +/- 0.9 Log(10) CFU g(-1) faeces (mean +/- SD, n = 6). Numbers of faecal lactobacilli increased significantly upon FMD ingestion. In addition, the numbers of bifidobacteria were higher on days 7 and 21 than on days 0 and 28 in both FMD fed and placebo fed groups. Consumption of Lact. casei had little discernible effect on other bacterial groups enumerated. Conclusions: Daily consumption of FMD enabled a probiotic Lact. casei strain to be maintained in the gastrointestinal tract of volunteers at a stable relatively high population level during the probiotic feeding period. Significance and Impact of the Study: The study has confirmed that this probiotic version of Lact. casei survives well within the human gastrointestinal tract.

Immunomodulatory effects of a probiotic drink containing Lactobacillus casei Shirota in healthy older volunteers

PURPOSE: There is growing evidence that probiotics confer health benefits to the host by modulating immune function, especially in older people, where immunosenescence is a feature even of healthy ageing. The aim of this study was to investigate the effect of a probiotic drink containing Lactobacillus casei Shirota (LcS) on immune function in a healthy non-immunocompromised older population. METHODS: Thirty healthy old volunteers were recruited into a randomized placebo-controlled, single-blind crossover study. The volunteers were supplemented with the probiotic drink containing 1.3 × 10(10) CFU LcS or skimmed milk per day for 4 weeks, followed by 4 weeks of washout and were crossed over to the other treatment. Peripheral blood and saliva samples were collected at baseline and end of each treatment. RESULTS: Probiotic consumption was associated with a significant increase in natural killer (NK) cell activity relative to baseline and a significant decrease in the mean fluorescence intensity of CD25 expression in the resting T cells compared with placebo. Additionally, there was a trend towards an increased ratio of IL-10 to IL-12 relative to baseline after LcS intake. CONCLUSIONS: Consumption of a probiotic drink containing LcS improved NK cell activity and tended to produce a more anti-inflammatory cytokine profile in an older population.

Dysregulated circulating dendritic cell function in ulcerative colitis is partially restored by probiotic strain Lactobacillus casei Shirota

BACKGROUND: Dendritic cells regulate immune responses to microbial products and play a key role in ulcerative colitis (UC) pathology. We determined the immunomodulatory effects of probiotic strain Lactobacillus casei Shirota (LcS) on human DC from healthy controls and active UC patients. METHODS: Human blood DC from healthy controls (control-DC) and UC patients (UC-DC) were conditioned with heat-killed LcS and used to stimulate allogeneic T cells in a 5-day mixed leucocyte reaction. RESULTS: UC-DC displayed a reduced stimulatory capacity for T cells (P < 0.05) and enhanced expression of skin-homing markers CLA and CCR4 on stimulated T cells (P < 0.05) that were negative for gut-homing marker β7. LcS treatment restored the stimulatory capacity of UC-DC, reflecting that of control-DC. LcS treatment conditioned control-DC to induce CLA on T cells in conjunction with β7, generating a multihoming profile, but had no effects on UC-DC. Finally, LcS treatment enhanced DC ability to induce TGFβ production by T cells in controls but not UC patients. CONCLUSIONS: We demonstrate a systemic, dysregulated DC function in UC that may account for the propensity of UC patients to develop cutaneous manifestations. LcS has multifunctional immunoregulatory activities depending on the inflammatory state; therapeutic effects reported in UC may be due to promotion of homeostasis.

Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge

Strategies for the development of new vaccines against Streptococcus pneumoniae infections try to overcome problems such as serotype coverage and high costs, present in currently available vaccines. Formulations based on protein candidates that can induce protection in animal models have been pointed as good alternatives. Among them, the Pneumococcal Surface Protein A (PspA) plays an important role during systemic infection at least in part through the inhibition of complement deposition on the pneumococcal surface, a mechanism of evasion from the immune system. Antigen delivery systems based on live recombinant lactic acid bacteria (LAB) represents a promising strategy for mucosal vaccination, since they are generally regarded as safe bacteria able to elicit both systemic and mucosal immune responses. In this work, the N-terminal region of clade I PspA was constitutively expressed in Lactobacillus casei and the recombinant bacteria was tested as a mucosal vaccine in mice. Nasal immunization with L. casei-PspA 1 induced anti-PspA antibodies that were able to bind to pneumococcal strains carrying both clade 1 and clade 2 PspAs and to induce complement deposition on the surface of the bacteria. In addition, an increase in survival of immunized mice after a systemic challenge with a virulent pneumococcal strain was observed. (C) 2008 Elsevier Masson SAS. All rights reserved.

Haemagglutination induced by Bordetella pertussis filamentous haemagglutinin adhesin (FHA) is inhibited by antibodies produced against FHA(430-873) fragment expressed in Lactobacillus casei

Filamentous haemagglutinin adhesin (FHA) is an important virulence factor from Bordetella pertussis related to the adhesion and spread of the bacteria through the respiratory tract. Three distinct domains have been characterized in mature FHA, and among them, the FHA(442-863) fragment was suggested to be responsible for the heparin-binding activity. In this study, we cloned the gene encoding the HEP fragment (FHA(430-873)) in a Lactobacillus casei-inducible expression vector based on the lactose operon. The recombinant bacteria, transformed with the resulting construct (L. casei-HEP), were able to express the heterologous protein depending on the sugar added to the culture. Subcutaneous inoculation of L. casei-HEP in Balb/C mice, using the cholera toxin B subunit as adjuvant, induced systemic anti-HEP antibodies that were able to inhibit in vitro erythrocyte haemagglutination induced by FHA. This is the first example of a B. pertussis antigen produced in lactic acid bacteria and opens new perspectives for alternative vaccine strategies against whooping cough.

Efeito do uso de Lactobacillus casei como cultura adjunta na qualidade tecnológica de queijo prato com reduzido teor de gordura

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Parâmetros de produção de leite de búfala fermentado por Lactobacillus casei

O leite de búfala foi fermentado por Lactobacillus casei, com diferentes concentrações de açúcar e tempos de fermentação, e estocado durante 30 dias a 5 e 10°C. Avaliaram-se a acidez, o pH e a viabilidade de L. casei nos diferentes tratamentos. O leite fermentado por 18 horas não apresentou os parâmetros requeridos para o produto, enquanto os fermentados por 22 e 24 horas apresentaram acidez e pH adequados. O tempo e a temperatura de estocagem influenciaram esses parâmetros. A viabilidade de L. casei inicial foi maior que 9 log UFC mL^-1 e a final, maior que 8 log UFC mL^-1, com influência da acidez.

Produção de L (+)-ácido lático por Lactobacillus casei Ke11 utilizando insumos agroindustriais

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Does the scientific evidence support the advertising claims made for products containing Lactobacillus casei and Bifidobacterium lactis? A systematic review

Background To analyse the scientific evidence that exists for the advertising claims made for two products containing Lactobacillus casei and Bifidobacterium lactis and to conduct a comparison between the published literature and what is presented in the corporate website. Methods Systematic review, using Medline through Pubmed and Embase. We included human clinical trials that exclusively measured the effect of Lactobacillus casei or Bifidobacterium lactis on a healthy population, and where the objective was related to the health claims made for certain products in advertising. We assessed the levels of evidence and the strength of the recommendation according to the classification criteria established by the Oxford Centre for Evidence Based Medicine (CEBM). We also assessed the outcomes of the studies published on the website that did not appear in the search. Results Of the 440 articles identified, 16 met the inclusion criteria. Only four (25%) of these presented a level of evidence of 1b and a recommendation grade of A, all corresponding to studies on product containing Bifidobacterium lactis, and only 12 of the 16 studies were published on the corporate website (47). Conclusions There is insufficient scientific evidence to support the health claims made for these products, especially in the case of product containing Lactobacillus casei.

Desarrollo de una bebida probiótica de Aloe perfoliata var. vera (Sabila) utilizando Lactobacillus casei shirota

Se desarrolló una bebida probiótica utilizando Aloe perfoliata var. vera (Sábila) y una cepa liofilizada de Lactobacillus casei shirota. a partir de la obtención del jugo de las hojas de la planta Aloe perfoliata var. vera (sábila); el cual se utilizó en proporciones 10% (50 mL), 15% (75 mL), 20% (100 mL); se le agregó Goma Xantan como estabilizante, Ácido Cítrico como regulador de la acidez, azúcar de caña sin refinar como edulcorante y agua purificada. Se procedió a pasteurizar la bebida, para la posterior incorporación del microrganismo estandarizado Lactobacillus casei shirota a la concentración de 107 UFC/mL. Se realizó la medición de los parámetros de pH y Grados Brix, y además la determinación de Escherichia coli al jugo de Aloe perfoliata var. vera (sábila) sin pasteurizar y pasteurizado; Así mismo se evaluó la estabilidad del microorganismo estandarizado Lactobacillus casei shirota a la concentración de 107 UFC/mL en el jugo de Aloe perfoliata var. vera, mediante recuento en placa en agar MRS, durante los periodos de 1, 2, 5, 8 y 15 días. Finalmente, se realizó la prueba sensorial de Análisis Descriptivo Cualitativo que se llevó a cabo con dos grupos de catadores, un grupo conformado 25 docentes y el otro por 25 estudiantes, a los cuales se les dió una muestra de 30 mL de la bebida para valorar las características sensoriales y la aceptabilidad de la bebida con relación al aspecto, color, olor, sabor (dulce, acido, residual), fluidez, grumosidad y calidad general. Tomando en cuenta del estudio estabilidad de Lactobacillus casei shirora en el jugo de Aloe perfoliata var. vera pasteurizado, se concluyó que la muestra que brinda mejor estabilidad al componente probiótico es la muestra 2. (15% de jugo de sábila) cuya de una concentración inicial de 7.00E+07 UFC/mL que se mantiene por espacio de 2 días con una concentración superior a 1.00E+06 UFC/mL, finalizando a los 15 días con 6.00E+07UFC/mL, alcanzando el requerimiento mínimo 106 necesario para que la bebida sea considerada como probiótica; además en la prueba sensorial del análisis descriptivo cuantitativo la muestra 2 (15% de jugo de sábila), presento una buena aceptabilidad, tanto en estudiantes como en docentes, ambos géneros; logrando obtener un resultado de calidad general aceptable; el tiempo de vida útil de la bebida preparada fue de 8 días, considerando tanto los valores de pH y Grados Brix que presentaron una disminución luego de transcurrido el octavo día de análisis.